Skip to main content
. Author manuscript; available in PMC: 2015 Jun 26.
Published in final edited form as: Oncogene. 2011 Apr 18;30(39):4129–4140. doi: 10.1038/onc.2011.124

Figure 8.

Figure 8

Proposed working model of the FXR-mediated regulation of HER2 expression in Tam-resistant breast cancer cells. In the absence of CDCA, HER2 expression is regulated by several serum factors, including NF-κB, acting through a regulatory region in HER2 promoter and enabling gene transcription. Upon CDCA treatment, FXR binds NF-κB inhibiting its recruitment on the response element located in the proximal HER2 promoter, causing displacement of RNA polymerase II with consequent repression of HER2 expression.